Pharmacokinetics (PK) of Trastuzumab Emtansine and Paclitaxel or Docetaxel in Patients with HER2-Positive MBC Previously Treated with a Trastuzumab-Containing Regimen.

被引：1
|
作者：
Lu, D. [1 ]
Modi, S. [1 ]
Elias, A. D. [1 ]
Agarwal, P. [1 ]
Yi, J-H [1 ]
Guardino, A. E. [1 ]
Althaus, B. L. [1 ]
Girish, S. [1 ]
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/0008-5472.SABCS11-P1-12-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-12-07
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
    Verma, Sunil
    Miles, David
    Gianni, Luca
    Krop, Ian E.
    Welslau, Manfred
    Baselga, Jose
    Pegram, Mark
    Oh, Do-Youn
    Dieras, Veronique
    Guardino, Ellie
    Fang, Liang
    Lu, Michael W.
    Olsen, Steven
    Blackwell, Kim
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (19): : 1783 - 1791
  • [22] Trastuzumab-Emtansine versus Capecitabine plus Lapatinib in Patients with previously treated HER2-positive metastatic Breast Cancer
    Ruckhaeberle, Eugen
    ONKOLOGE, 2017, 23 (11): : 940 - 942
  • [23] Population pharmacokinetics (Pop PK) of MYL-1401O (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2-positive metastatic breast cancer (mBC)
    Owen, Joel
    Rackley, Russell
    Liu, Mark
    Fuentes-Alburo, Adolfo
    Idris, Tazeen
    Loganathan, Subramanian
    Barve, Abhijit
    Waller, Cornelius F.
    Rugo, Hope S.
    CANCER RESEARCH, 2021, 81 (04)
  • [24] Phase II study of trastuzumab with irinotecan in HER2-positive gastric cancer previously treated with trastuzumab
    Hatanaka, Kazuteru
    Kawamoto, Yasuyuki
    Yuki, Satoshi
    Meguro, Takashi
    Uebayashi, Minoru
    Abe, Masakazu
    Nakamura, Michio
    Okuda, Hiroyuki
    Sakata, Yuh
    Komatsu, Yoshito
    ANNALS OF ONCOLOGY, 2017, 28
  • [25] KATHERINE: Trastuzumab emtansine vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer
    Mamounas, Eleftherios P.
    Geyer, Charles E., Jr.
    Huang, Chiun-Sheng
    Mano, Max S.
    Loibl, Sibylle
    Untch, Michael
    Wolmark, Norman
    Rastogi, Priya
    Schneeweiss, Andreas
    Redondo, Andres
    Fischer, Hans H.
    Jacot, William
    Conlin, Alison K.
    Arce-Salinas, Claudia
    Wapnir, Irene L.
    Jackisch, Christian
    DiGiovanna, Michael P.
    Fasching, Peter A.
    Crown, John P.
    Wuelfing, Pia
    Shao, Zhimin
    Caremoli, Elena Rota
    Wu, Haiyan
    Lam, Lisa H.
    Tesarowski, David
    Smitt, Melanie
    Douthwaite, Hannah
    Singel, Stina M.
    von Minckwitz, Gunter
    SWISS MEDICAL WEEKLY, 2019, 149 : 13S - 13S
  • [26] Trastuzumab emtansine (T-DM1) in previously treated HER2-positive metastatic breast cancer (MBC): Results from an expanded access study
    Yardley, Denise Aysel
    Krop, Ian E.
    LoRusso, Patricia
    Robert, Nicholas J.
    Mayer, Musa
    Abidoye, Oyewale O.
    Lai, Catherine
    Yoo, Bongin
    Perez, Edith A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26)
  • [27] Trastuzumab deruxtecan in previously treated advanced HER2-positive gastric cancer
    Pamuk, Aylin
    Kuetting, Fabian
    Alakus, Hakan
    Bruns, Christiane
    ONKOLOGE, 2021, 27 (01): : 74 - 76
  • [28] Lapatinib with trastuzumab for heavily treated HER2-positive metastatic breast cancer (mBC).
    Sotelo, Miguel J.
    Manso, Luis
    Garcia Saenz, Jose Angel
    Ciruelos, Eva M.
    Moreno, Fernando
    Mendiola, Cesar
    Callata, Hector
    Ghanem, Ismael
    Cabezas, Santiago
    Gonzalez-Larriba, Jose-Luis
    Diaz Rubio, Eduardo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [29] Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
    von Minckwitz, G.
    Huang, C. -S.
    Mano, M. S.
    Loibl, S.
    Mamounas, E. P.
    Untch, M.
    Wolmark, N.
    Rastogi, P.
    Schneeweiss, A.
    Redondo, A.
    Fischer, H. H.
    Jacot, W.
    Conlin, A. K.
    Arce-Salinas, C.
    Wapnir, I. L.
    Jackisch, C.
    DiGiovanna, M. P.
    Fasching, P. A.
    Crown, J. P.
    Wuelfing, P.
    Shao, Z.
    Caremoli, E. Rota
    Wu, H.
    Lam, L. H.
    Tesarowski, D.
    Smitt, M.
    Douthwaite, H.
    Singel, S. M.
    Geyer, C. E., Jr.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (07): : 617 - 628
  • [30] Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
    Geyer Jr, Charles E.
    Untch, Michael
    Huang, Chiun-Sheng
    Mano, Max S.
    Mamounas, Eleftherios P.
    Wolmark, Norman
    Rastogi, Priya
    Schneeweiss, Andreas
    Redondo, Andres
    Fischer, Hans H.
    D'Hondt, Veronique
    Conlin, Alison K.
    Guarneri, Valentina
    Wapnir, Irene L.
    Jackisch, Christian
    Arce-Salinas, Claudia
    Fasching, Peter A.
    Digiovanna, Michael P.
    Crown, John P.
    Wuelfing, Pia
    Shao, Zhimin
    Caremoli, Elena Rota
    Bonnefoi, Herve R.
    Hennessy, Bryan T.
    Stamatovic, Ljiljana
    Castro-Salguero, Hugo
    Brufsky, Adam M.
    Knott, Adam
    Siddiqui, Asna
    Lambertini, Chiara
    Boulet, Thomas
    Nyawira, Beatrice
    Restuccia, Eleonora
    Loibl, Sibylle
    KATHERINE Study Grp
    NEW ENGLAND JOURNAL OF MEDICINE, 2025,
12345